India’s pharmaceutical sector, valued at approximately $55–65 billion in 2025, ranks third globally by volume and fourteenth by value. The industry grew 7.8% year-on-year, supplying 20% of the world’s generic medicines and meeting over half of UNICEF’s vaccine needs. It is projected to reach $120–130 billion by 2030, driven by innovation and exports.
Nifty Pharma traded flat at 22,208.30 despite Donald Trump’s threat of imposing a 200% tariff on pharmaceutical imports to the U.S. The market is likely priced in uncertainty, awaiting clarity on policy execution. Indian pharma’s global exposure and regulatory adaptability may have cushioned immediate investor reaction to the geopolitical risk.
The US President’s remarks on potential levies for pharmaceutical companies suggest regulatory pressure may increase, but no immediate action is planned. With an indicative window of 12–18 months, companies may have time to adjust. However, the absence of formal orders or timelines adds uncertainty to the policy’s implementation.
Despite Trump’s April warning of unprecedented pharma tariffs targeting 60 countries, market reaction has remained muted. The Nifty Pharma index has shown limited movement since, reflecting investor caution rather than panic. However, with the index down 5.5% year-to-date, sentiment remains under pressure amid ongoing geopolitical and regulatory uncertainty.
India currently imposes a 10% tariff on US pharma imports, while the US allows duty-free access to Indian medicines. Analysts suggest that any reciprocal US tariffs, if implemented, would likely match India’s 10%. While not overly disruptive, such tariffs could impact pricing dynamics and competitiveness of Indian exporters marginally.
Also read: Power transmission stock hits 5% upper circuit after announcing ₹170 Cr capacity expansion plan
Here are the pharma stocks after Donald Trump’s 200% tariff threat;
| Company Name | CMP | Movement |
| Sun Pharmaceutical Industries Ltd | 1,671.00 | 0.1% down |
| Zydus Lifesciences Ltd | 972.05 | 1.13 % down |
| Lupin Ltd | 1,931.70 | 0.50 % up |
| Aurobindo Pharma Ltd | 1,147.20 | 0.1% down |
| Abbott India Ltd | 34,230.00 | 0.25% up |
| Cipla | 1,489.90 | 0.11% up |
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
